Allogene Therapeutics, Inc. Logo

Allogene Therapeutics, Inc.

Developing off-the-shelf CAR T-cell therapies for cancer and autoimmune diseases.

ALLO | US

Overview

Corporate Details

ISIN(s):
US0197701065
LEI:
Country:
United States of America
Address:
210 EAST GRAND AVENUE, 94080 SOUTH SAN FRANCISCO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T-cell (AlloCAR T™) therapies. The company's 'off-the-shelf' product platform utilizes T-cells from healthy donors to create readily available treatments designed to be more accessible, scalable, and reliable than patient-specific autologous therapies. Its clinical pipeline targets hematologic malignancies (blood cancers), solid tumors, and autoimmune diseases. Key investigational programs include cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma (LBCL), ALLO-316 for renal cell carcinoma (ccRCC), and ALLO-329 for autoimmune diseases. Allogene leverages multiplex gene-engineering and gene-editing capabilities to develop its product candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Allogene Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Allogene Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Allogene Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Xspray Pharma Logo
Develops improved cancer drugs (PKIs) using patented tech to circumvent secondary patents.
Sweden
XSPRAY
YD Bio Ltd Logo
Developing blood-based cancer detection and regenerative therapies for biopharma partners.
United States of America
YDES
YUHAN CORPORATION Logo
A pharmaceutical & chemical firm developing drugs, supplements, consumer products, and APIs.
South Korea
000100
YUKI GOSEI KOGYO CO.,LTD. Logo
Manufactures fine chemicals, amino acids, and APIs via organic synthesis for global industries.
Japan
4531
Zai Lab Ltd Logo
Global biopharma firm developing therapies for oncology, immunology, neuroscience & infectious diseases.
United States of America
ZLAB
Zealand Pharma Logo
Developing innovative peptide medicines for metabolic and inflammatory diseases.
Denmark
ZEAL
Zelluna ASA Logo
Developing off-the-shelf TCR-NK cell therapies to treat patients with solid cancers.
Norway
ULTI
Zenas BioPharma, Inc. Logo
Clinical-stage biopharma developing immunology-based therapies for autoimmune diseases.
United States of America
ZBIO
Zentalis Pharmaceuticals, Inc. Logo
Develops small molecule cancer drugs, led by a first-in-class oral WEE1 inhibitor for tumors.
United States of America
ZNTL

Talk to a Data Expert

Have a question? We'll get back to you promptly.